Blood and Lymphatic Cancer: Targets and Therapy

Call For Papers

To see where Blood and Lymphatic Cancer: Targets and Therapy is indexed online view the Journal Metrics. 

What is the advantage to you of publishing in Blood and Lymphatic Cancer: Targets and Therapy?

• It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove Medical Press website.
• Unlike many traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.
• The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. Blood and Lymphatic Cancer: Targets and Therapy has a quicker turnaround time than this. Generally peer review is complete within 3-4 weeks and the editor’s decision within 2-14 days of this. It is therefore very rare to have to wait more than 6 weeks for first editorial decision.
• Many authors have found that our peer reviewers’ comments substantially add to their final papers.

To recover our editorial and production costs, and continue to provide our content at no cost to readers, we charge authors or their institution an article publishing charge.

PubMed Central
Blood and Lymphatic Cancer: Targets and Therapy is indexed on PubMed Central (title abbreviation: Blood Lymphat Cancer). All published papers in this journal are submitted to PubMed for indexing straight away.

Become a Favored Author and receive real benefits
If you haven't already joined the Dove Medical Press Favored Author Program I would encourage you to do so.  Why? To receive real benefits like fast-tracking and a personal coordinator for your paper, as well as a discount on the publication processing fee. Click here to go through to the Favored Author signup page.

Yours sincerely
Dr Wilson Gonsalves
Editor-in-Chief
Blood and Lymphatic Cancer: Targets and Therapy 

Email: Editor-in-Chief